NORTHWEST BIOTHERAPEUTICS, INC. (OTCMKTS:NWBO) Files An 8-K Other Events
Item 8.01. Other Events.

Northwest Biotherapeutics, Inc. (the “Company”) has received a number of shareholder inquiries asking for clarification whether the 331 patients enrolled in its Phase III DCVax®-L Trial includes the 32 patients in a Pseudo-Progressor arm or those 32 patients are in addition to the 331 patients enrolled.

The Company is clarifying that the 32 patients in the Pseudo-Progressor Arm are in addition to the 331 patients enrolled in the Main Arm of the Trial and are not included in the 331.  The Company notes that there are 90 patients in other separate arms of the Trial in addition to the 331 patients in the Main Arm, making a total of 421 patients.  The 90 patients include the 32 patients in the Pseudo-Progressor Arm, 55 patients in the Information Arm, and 3 patients who were enrolled at the very beginning of the Trial when it was randomized but not yet blinded.  The Trial was blinded after those initial patients were enrolled.  In addition to these 421 patients, the Company has treated a substantial number of patients on a compassionate basis under an Expanded Access Protocol.

About NORTHWEST BIOTHERAPEUTICS, INC. (OTCMKTS:NWBO)

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

NORTHWEST BIOTHERAPEUTICS, INC. (OTCMKTS:NWBO) Recent Trading Information

NORTHWEST BIOTHERAPEUTICS, INC. (OTCMKTS:NWBO) closed its last trading session up +0.005 at 0.475 with 1,025,526 shares trading hands.